After Hours Most Active for Jan 29, 2025 : NVDA, INTC, LUMN, VCSH, TSLL, TSLA, SFIX, SCHW, CCL, EW, UBER, T
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 29 2025
0mins
Should l Buy EW?
Source: NASDAQ.COM
After Hours Market Activity: The NASDAQ 100 After Hours Indicator is up to 21,448.89 with a total volume of 161,238,880 shares traded, highlighting active stocks like NVIDIA and Intel, which are showing positive movements ahead of their upcoming earnings reports.
Earnings Forecasts: Several companies, including Intel, Lumen Technologies, and Uber, are set to release earnings reports soon, with forecasts indicating potential increases in earnings per share compared to the previous year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EW?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EW
Wall Street analysts forecast EW stock price to rise
24 Analyst Rating
16 Buy
8 Hold
0 Sell
Moderate Buy
Current: 78.200
Low
84.00
Averages
96.52
High
105.00
Current: 78.200
Low
84.00
Averages
96.52
High
105.00
About EW
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Edwards Lifesciences to Announce Q1 2026 Results
- Earnings Announcement Timing: Edwards Lifesciences plans to release its operating results for the quarter ending March 31, 2026, after market close on April 23, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call at 5:00 p.m. ET on the same day, with participants able to dial (877) 704-2848 or (201) 389-0893, aiming to engage investors in a detailed discussion of performance and future outlook.
- Investor Relations Platform: The conference call will be available live and archived on the Edwards Lifesciences
See More
Latest Research Reports on Pharma and Tech Stocks
- Eli Lilly Growth Momentum: Eli Lilly (LLY) shares have risen 13.89% over the past six months, outperforming the pharmaceutical industry’s 9.26% growth, primarily driven by strong demand for its GLP-1 drugs, Mounjaro and Zepbound, with growth expected to continue into 2026.
- Mastercard Investment Pressures: Mastercard (MA) shares have declined 11.9% in the past six months, despite a 16% year-over-year increase in net revenues for 2025, as rising operating expenses due to accelerated investments are expected to grow in low double digits, impacting profitability.
- Strong Demand for AMD: AMD (AMD) shares have gained 12.4% over the past six months, benefiting from robust demand for EPYC processors, particularly in cloud and enterprise workloads, which is expected to continue driving company growth.
- Stratus Liquidation Strategy: Stratus Properties (STRS) shares have surged 55.2% in the past six months, implementing a liquidation strategy in March 2026, with estimated distributions of $29.73 to $37.69 per share, supported by strong liquidity for controlled asset sales.
See More
Investment Opportunities in Asian Small Caps Amid Market Fluctuations
- Complex Market Dynamics: Amid geopolitical tensions and fluctuating energy prices, Asian markets exhibit mixed performances across key indices, prompting investors to carefully assess market dynamics to seize potential opportunities.
- Attraction of Small Caps: Small-cap stocks are gaining attention for their growth potential and resilience, particularly when insider buying activity indicates confidence in future prospects, making them appealing for investors.
- Bell Financial Group Performance: With a market cap of approximately A$0.37 billion, Bell Financial Group is projected to achieve revenue of A$299.18 million and net income of A$36.01 million by 2025, reflecting a robust performance in the financial services sector with a potential annual growth rate of 7%.
- Greentown Management Holdings Update: Greentown Management Holdings, valued at approximately CN¥7.52 billion, has reported a decline in sales and net income for 2025; however, CEO Junfeng Wang's acquisition of 500,000 shares in March 2026 demonstrates confidence in the company's future growth prospects.
See More
Anteris Aims to Reshape $10B Heart Market with Innovative Valve
- Market Opportunity Identification: Anteris Technologies is developing a new TAVR valve through its DurAVR program to meet the needs of younger patients requiring heart valve replacements, with the market projected to reach $10 billion by 2028, indicating significant growth potential.
- Design Innovation: Unlike existing valves, DurAVR features a single-piece molded design combined with a balloon-expandable delivery system, aiming to provide superior hemodynamic performance and address the trade-off between ease of use and performance seen in traditional valves.
- Clinical Trial Progress: Anteris has treated over 130 patients in early studies, demonstrating favorable hemodynamic performance with low pressure gradients and minimal prosthesis-patient mismatch, with the next phase being the PARADIGM pivotal trial enrolling around 1,000 patients for comparative analysis.
- Strategic Investment Support: In early 2026, Anteris completed a $320 million capital raise, including a $90 million strategic investment from Medtronic, validating the technology and market opportunity despite Medtronic being a competitor.
See More
Market Watch: Corporate Dynamics and Analysis
- Nike's Disappointing Performance: Despite beating revenue and earnings expectations, Nike issued weak guidance due to inventory issues and a slowdown in North American growth, prompting downgrades from Goldman, JPMorgan, and Bank of America, reflecting market concerns about its future performance.
- RH's Poor Earnings Report: Luxury home furnishings maker RH fell short on key metrics in its fourth quarter, and its current quarter guidance was also weak, impacted by tariffs and a sluggish housing market, leading to an 18% drop in shares, although its full-year cash flow guidance improved, the overall outlook remains bleak.
- Arm's Price Target Increase: Wells Fargo raised Arm's price target from $165 to $175, with analysts optimistic about Arm's entry into the data center CPU market with its first in-house silicon offering, reiterating a buy rating, indicating strong market confidence in its competition against Intel and AMD.
- Boeing Stock Rating Upgrade: Wells Fargo upgraded Boeing's stock to buy with a price target of $250, implying over 25% upside from yesterday's close, as analysts favor Boeing's free cash flow recovery and overall turnaround under CEO Kelly Ortberg, suggesting potential returns for investors.
See More
Analyst Opinions Impact Edwards Lifesciences Ranking
- Analyst Ranking Mechanism: The ranking is formed by averaging analyst opinions for each component, thereby ranking 500 components and reflecting market perceptions of various companies.
- Stock Performance Review: Year-to-date, Edwards Lifesciences' stock price has decreased by approximately 6.2%, indicating a cautious market sentiment regarding its future performance, which may affect investor confidence.
- Diversity of Market Opinions: While the ranking provides an overall market perspective, the author emphasizes that these views do not necessarily reflect those of Nasdaq, showcasing the diversity and complexity of analyst opinions.
- Impact on Investor Decisions: Analyst opinions and rankings can influence investor decisions, particularly in light of the stock price decline, prompting investors to reassess their investment strategies in Edwards Lifesciences.
See More
Edwards Lifesciences to Announce Q1 2026 Results
- Earnings Announcement Timing: Edwards Lifesciences plans to release its operating results for the quarter ending March 31, 2026, after market close on April 23, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call at 5:00 p.m. ET on the same day, with participants able to dial (877) 704-2848 or (201) 389-0893, aiming to engage investors in a detailed discussion of performance and future outlook.
- Investor Relations Platform: The conference call will be available live and archived on the Edwards Lifesciences
See More
Latest Research Reports on Pharma and Tech Stocks
- Eli Lilly Growth Momentum: Eli Lilly (LLY) shares have risen 13.89% over the past six months, outperforming the pharmaceutical industry’s 9.26% growth, primarily driven by strong demand for its GLP-1 drugs, Mounjaro and Zepbound, with growth expected to continue into 2026.
- Mastercard Investment Pressures: Mastercard (MA) shares have declined 11.9% in the past six months, despite a 16% year-over-year increase in net revenues for 2025, as rising operating expenses due to accelerated investments are expected to grow in low double digits, impacting profitability.
- Strong Demand for AMD: AMD (AMD) shares have gained 12.4% over the past six months, benefiting from robust demand for EPYC processors, particularly in cloud and enterprise workloads, which is expected to continue driving company growth.
- Stratus Liquidation Strategy: Stratus Properties (STRS) shares have surged 55.2% in the past six months, implementing a liquidation strategy in March 2026, with estimated distributions of $29.73 to $37.69 per share, supported by strong liquidity for controlled asset sales.
See More
Investment Opportunities in Asian Small Caps Amid Market Fluctuations
- Complex Market Dynamics: Amid geopolitical tensions and fluctuating energy prices, Asian markets exhibit mixed performances across key indices, prompting investors to carefully assess market dynamics to seize potential opportunities.
- Attraction of Small Caps: Small-cap stocks are gaining attention for their growth potential and resilience, particularly when insider buying activity indicates confidence in future prospects, making them appealing for investors.
- Bell Financial Group Performance: With a market cap of approximately A$0.37 billion, Bell Financial Group is projected to achieve revenue of A$299.18 million and net income of A$36.01 million by 2025, reflecting a robust performance in the financial services sector with a potential annual growth rate of 7%.
- Greentown Management Holdings Update: Greentown Management Holdings, valued at approximately CN¥7.52 billion, has reported a decline in sales and net income for 2025; however, CEO Junfeng Wang's acquisition of 500,000 shares in March 2026 demonstrates confidence in the company's future growth prospects.
See More
Anteris Aims to Reshape $10B Heart Market with Innovative Valve
- Market Opportunity Identification: Anteris Technologies is developing a new TAVR valve through its DurAVR program to meet the needs of younger patients requiring heart valve replacements, with the market projected to reach $10 billion by 2028, indicating significant growth potential.
- Design Innovation: Unlike existing valves, DurAVR features a single-piece molded design combined with a balloon-expandable delivery system, aiming to provide superior hemodynamic performance and address the trade-off between ease of use and performance seen in traditional valves.
- Clinical Trial Progress: Anteris has treated over 130 patients in early studies, demonstrating favorable hemodynamic performance with low pressure gradients and minimal prosthesis-patient mismatch, with the next phase being the PARADIGM pivotal trial enrolling around 1,000 patients for comparative analysis.
- Strategic Investment Support: In early 2026, Anteris completed a $320 million capital raise, including a $90 million strategic investment from Medtronic, validating the technology and market opportunity despite Medtronic being a competitor.
See More
Market Watch: Corporate Dynamics and Analysis
- Nike's Disappointing Performance: Despite beating revenue and earnings expectations, Nike issued weak guidance due to inventory issues and a slowdown in North American growth, prompting downgrades from Goldman, JPMorgan, and Bank of America, reflecting market concerns about its future performance.
- RH's Poor Earnings Report: Luxury home furnishings maker RH fell short on key metrics in its fourth quarter, and its current quarter guidance was also weak, impacted by tariffs and a sluggish housing market, leading to an 18% drop in shares, although its full-year cash flow guidance improved, the overall outlook remains bleak.
- Arm's Price Target Increase: Wells Fargo raised Arm's price target from $165 to $175, with analysts optimistic about Arm's entry into the data center CPU market with its first in-house silicon offering, reiterating a buy rating, indicating strong market confidence in its competition against Intel and AMD.
- Boeing Stock Rating Upgrade: Wells Fargo upgraded Boeing's stock to buy with a price target of $250, implying over 25% upside from yesterday's close, as analysts favor Boeing's free cash flow recovery and overall turnaround under CEO Kelly Ortberg, suggesting potential returns for investors.
See More
Analyst Opinions Impact Edwards Lifesciences Ranking
- Analyst Ranking Mechanism: The ranking is formed by averaging analyst opinions for each component, thereby ranking 500 components and reflecting market perceptions of various companies.
- Stock Performance Review: Year-to-date, Edwards Lifesciences' stock price has decreased by approximately 6.2%, indicating a cautious market sentiment regarding its future performance, which may affect investor confidence.
- Diversity of Market Opinions: While the ranking provides an overall market perspective, the author emphasizes that these views do not necessarily reflect those of Nasdaq, showcasing the diversity and complexity of analyst opinions.
- Impact on Investor Decisions: Analyst opinions and rankings can influence investor decisions, particularly in light of the stock price decline, prompting investors to reassess their investment strategies in Edwards Lifesciences.
See More
